Leukemia Research
Volume 30, Issue 2 , Pages 153-163 , February 2006

Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas

Received 9 August 2004 ,Accepted 13 June 2005.

References 

  1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512
  2. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 1997;11:342–345
  3. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27KIP1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem. 1999;274:13886–13893
  4. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27KIP1 in G1 and S phase. Nature. 2001;413:323–327
  5. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent kinase inhibitor p27KIP1 is instigated by JAB1. Nature. 1999;398:160–165
  6. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, et al. p27 cytoplasmic localisation is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001;20:6672–6682
  7. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al. A growth factor-dependent nuclear kinase phosphorylates p27KIP1 and regulates cell cycle progression. EMBO J. 2002;21:3390–3401
  8. Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27KIP1 by PKB/AKT-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–1144
  9. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/AKT mediates cell-cycle progression by phosphorylation of p27KIP1 at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8:1145–1152
  10. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/AKT phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8:1153–1160
  11. Sekimoto T, Fukumoto M, Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27KIP1. EMBO J. 2004;23:1934–1942
  12. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–234
  13. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27KIP1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227–230
  14. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27KIP1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313–323
  15. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas—prognostic implications. Blood. 1998;92:770–777
  16. Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol Mateo M, Sanchez-Verde L, Villuendas R, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue— p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol. 1997;151:151–160
  17. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220–1235
  18. Barnouin K, Fredersdorf S, Eddaoudi A, Mittnacht S, Pan LX, Du MQ, et al. Antiproliferative function of p27KIP1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene. 1999;18:6388–6397
  19. Moller MB, Skjodt K, Mortensen LS, Pedersen NT. Clinical significance of cyclin-dependent kinase inhibitor p27KIP1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27KIP1. Br J Haematol. 1999;105:730–736
  20. Vrhovac R, Delmer A, Tang RP, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27KIP1 in chronic B cell lymphocytic leukemia. Blood. 1998;91:4694–4700
  21. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med. 1998;187:1825–1838
  22. Fredrickson TN, Lennert K, Chattopadhyay SK, Morse HC, Hartley JW. Splenic marginal zone lymphomas of mice. Am J Pathol. 1999;154:805–812
  23. Hartley JW, Chattopadhyay SK, Lander MR, Taddesse-Heath L, Naghashfar Z, Morse HC, et al. Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses. Lab Invest. 2000;80:159–169
  24. Qi CF, Hori M, Coleman AE, Torrey TA, Taddesse-Heath L, Ye BH, et al. Genomic organisation and expression of BCL6 in murine B cell lymphomas. Leuk Res. 2000;24:719–732
  25. Morse III HC, Qi CF, Chattopadhyay SK, Hori M, Taddesse-Heath L, Ozato K, et al. Fredrickson TN.Combined histiologic and molecular features reveal previously unappreciated subsets of lymphoma in AKXD recombinant inbred mice. Leuk Res. 2001;25:719–733
  26. Morse III HC, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, et al. Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100:246–258
  27. Ward JM, Mahler JF, Maronpot RR, Sundberg JP, Frederickson RM. Pathology of Genetically Engineered Mice. Ames, IA: Iowa State University Press; 2000;
  28. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, et al. Burkitt lymphoma in the mouse. J Exp Med. 2000;192:1183–1190
  29. Fredrickson TN, Harris AW. Atlas of Mouse Hematopathology. Amsterdam: Harwood Academic Publishers; 2000;
  30. Potter M, Wiener F. Plasmacytomagenesis in mice—model of neoplastic development dependent upon chromosomal translocations. Cancinogenesis. 1992;13:1681–1697
  31. Shin MS, Fredrickson TN, Hartley JW, Suzuki T, Agaki K, Morse HC. High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas. Cancer Res. 2004;64:4419–4427
  32. Qi CF, Chattopadhyay SK, Lander M, Kim Y, Fredrickson TN, Hartley JW, et al. Expression of cyclin D1 in mouse B cell lymphomas of different histologic types and differentiation stages. Leuk Res. 1998;22:395–404
  33. Pruneri G, Carboni N, Baldini L, Intini D, Colombi M, Bertolini F, et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Human Pathol. 2003;34:41–47
  34. Kremer M, Ott G, Nathrath I, Specht K, Stecker K, Alexiou C, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;205:92–101
  35. Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175–182
  36. Vrhovac R, Delmer A, Tang RP, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood. 1998;91:4694–4700
  37. Lin ZS, Lim S, Lim MS. Growth regulation by p27Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas. Br J Haematol. 2003;121:739–748
  38. Quintanilla-Martinez L, Davies-Hill T, Fend F, Calzada-Wack J, Sorbara L, Campo E, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (Mcl): implications for pathogenesis. Blood. 2003;101:3181–3187
  39. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, et al. Anomalous high p27/Kip1 expression in a subset of aggressive B cell lymphomas is associated with cyclin D3 overexpression. p27/Kip1-cyclin D3 colocalization in tumor cells. Blood. 1999;94:765–772
  40. Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59–68
  41. Zhang W, Bergamaschi D, Jin B, Lu X. Posttranslational modifications of p27Kip1 determine its binding specificity to different cyclins and cdks in vivo. Blood. 2005;105:3691–3698
  42. Doglioni C, Chiarelli C, Macri E, Tos APD, Meggiolaro E, Dalla Palma P, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185:159–166
  43. Camacho FI, Garcia JF, Sanchez-Verde L, Saez AI, Sanchez-Verde L, Saez AI, et al. Unique phenotypic profile of monocytoid B cells—differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma. Am J Pathol. 2001;158:1363–1369
  44. Ravnik SE, Wolgemuth DJ. Regulation of meiosis during mammalian spermatogenesis: the A-type cyclins and their associated cyclin-dependent kinases are differentially expressed in the germ-cell lineage. Dev Biol. 1999;207:408–418
  45. Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, Pandolfi PP, et al. Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci USA. 2001;98:6853–6858
  46. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 1998;92:1743–1748
  47. Rummel M, deVos S, Hoelzer D, Koeffler HP, Hofmann WK. Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymph. 2004;45:49–54
  48. Morse HC, McCarty T, Qi CF, Torrey TA, Naghashfar Z, Chattopadhyay SK, et al. B lymphoid neoplasms of mice: characteristics of naturally occurring and engineered diseases and relationships to human disorders. Adv Immunol. 2004;81:97–121
  49. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCFSkp2-Cks1 ubiquitin ligase by the APC/CCdh1 ubiquitin ligase [Letter]. Nature. 2004;428:190–193
  50. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex [Letter]. Nature. 2004;428:194–198
  51. Piva R, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol Cell Biol. 2002;22:8375–8387
  52. Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, et al. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene. 2002;21:7235–7240
  53. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 2001;98:10983–10985

PII: S0145-2126(05)00263-8

doi: 10.1016/j.leukres.2005.06.025

Leukemia Research
Volume 30, Issue 2 , Pages 153-163 , February 2006

Article Tools

* Image Usage & Resolution